How should I manage a patient with peritonitis, including resuscitation, empiric broad‑spectrum intravenous antibiotics, and urgent surgical source control?

Management of Peritonitis

Patients with peritonitis require immediate broad-spectrum intravenous antibiotics within one hour of diagnosis, aggressive fluid resuscitation, and urgent surgical source control—delays beyond 24 hours significantly increase mortality. 1, 2

Immediate Resuscitation and Stabilization

• Begin aggressive intravenous fluid resuscitation immediately to correct hypotension, oliguria, and lactic acidosis; do not delay source control while optimizing hemodynamics—resuscitation should continue during surgical intervention. 1, 2
• Obtain blood cultures before antibiotic administration in all patients; collect intraoperative peritoneal fluid (minimum 1–2 mL) and inoculate directly into aerobic and anaerobic transport media. 3, 2
• Monitor for signs of septic shock: hypotension, altered mental status, oliguria, and elevated lactate levels warrant immediate escalation of care. 2

Empiric Broad-Spectrum Antibiotic Therapy

For Community-Acquired Peritonitis (Non-Critically Ill)

• Initiate piperacillin-tazobactam 3.375 g IV every 6 hours as first-line empiric therapy for stable, immunocompetent patients with community-acquired secondary peritonitis. 3
• This regimen provides adequate coverage of E. coli, Klebsiella, Streptococcus species, and anaerobes including Bacteroides fragilis. 3, 4

For Critically Ill or Septic Shock Patients

• Administer a carbapenem (meropenem 1–2 g IV every 8 hours, imipenem-cilastatin 500 mg–1 g IV every 6–8 hours, or doripenem 500 mg IV every 8 hours) immediately in patients with septic shock, severe sepsis, or high risk for ESBL-producing organisms. 1, 3, 5
• Use higher loading doses of hydrophilic β-lactam antibiotics because sepsis-induced plasma dilution reduces drug concentrations independent of renal function. 3
• Each hour of delay in antibiotic administration increases mortality; ensure antibiotics are given within the first hour of diagnosis. 3, 2

Risk Factors Requiring Broader Coverage

• Add vancomycin 15 mg/kg IV every 12 hours when any of the following are present: 3
  • Antibiotic exposure within the prior 90 days (strongest predictor of multidrug-resistant organisms)
  • Hospitalization longer than 1 week
  • ICU stay in the prior 90 days
  • Immunosuppression or corticosteroid use
• Add empiric echinocandin antifungal therapy (e.g., caspofungin, micafungin) for healthcare-associated infections, particularly in frail or immunocompromised patients with recent abdominal surgery or anastomotic leakage. 1, 3

Hospital-Acquired or Tertiary Peritonitis

• Use carbapenems as first-line therapy due to high rates of ESBL-producing Enterobacteriaceae, Pseudomonas aeruginosa, and multidrug-resistant organisms in nosocomial infections. 3, 6
• Do not use narrow-spectrum antibiotics in hospital-acquired peritonitis—resistance patterns demand broader coverage. 2

Urgent Surgical Source Control

Source control is the primary treatment for secondary peritonitis; antibiotics are adjunctive only. 1, 3, 2

Timing of Intervention

• Perform definitive source control as soon as possible after diagnosis, ideally within 24 hours; delays beyond this threshold markedly increase mortality. 1, 7
• Operating room latency ≥60 hours independently predicts need for relaparotomy and death. 1, 7
• Early relaparotomy within 24 hours of diagnosis improves outcomes in postoperative peritonitis; delays beyond 48 hours result in mortality rates exceeding 75%. 3, 7

Source Control Objectives

• Drain all infected fluid collections and abscesses. 1, 2
• Control ongoing peritoneal contamination by resecting or suturing perforated viscera, removing infected organs (appendix, gallbladder), debriding necrotic tissue, and repairing or resecting ischemic bowel. 1, 2
• Restore anatomical and physiological function through primary anastomosis or exteriorization of bowel as clinically appropriate. 1, 2

Surgical Approach

• Percutaneous drainage is preferred over open surgery when technically feasible, showing lower mortality (approximately 4% vs. 15%). 3
• Open laparotomy or laparoscopy is required for diffuse peritonitis, failed percutaneous drainage, or anatomically complex cases. 3, 2
• Consider damage control surgery (Hartmann's procedure or resection with diverting stoma) in physiologically deranged patients with ongoing sepsis to prevent abdominal compartment syndrome. 1, 2

Highly Selected Exceptions to Immediate Surgery

• Non-operative management may be considered only in hemodynamically stable patients responding to antibiotics with: 1, 2
  • Perforated diverticulitis with abscess <4 cm diameter
  • Peri-appendiceal phlegmon or small abscess
  • Small perforated peptic ulcer with minimal contamination
  • CT findings of pericolic air only without diffuse peritonitis or distant free air
• Distant free air, hemodynamic instability, or diffuse peritonitis mandates immediate surgical intervention. 1, 2

Duration of Antibiotic Therapy

• Administer antibiotics for 3–5 days (a fixed 4-day course is optimal) after adequate source control and clinical improvement. 1, 3, 2
• Short-course therapy (3–5 days) is strongly recommended even for critically ill patients when source control is sufficient; outcomes are equivalent to longer courses. 3, 2
• Do not extend therapy beyond 5–7 days when source control is achieved and the patient is improving; prolonged courses increase antimicrobial resistance, Clostridioides difficile infection risk, and drug toxicity without improving outcomes. 3, 2
• For uncomplicated infections (e.g., uncomplicated appendicitis or cholecystitis) where source control is definitive, postoperative antibiotics are not required. 3, 2

Culture-Guided De-escalation

• De-escalate to the narrowest effective regimen within 24–48 hours once culture results and susceptibilities are available, using local resistance patterns. 3, 2
• This de-escalation approach is a core component of antimicrobial stewardship and reduces selection pressure for resistant organisms without compromising clinical outcomes. 3

Monitoring for Treatment Failure

• If fever, leukocytosis, or signs of peritonitis persist beyond 5–7 days of appropriate therapy, obtain an abdominal CT scan to assess for inadequate source control, residual abscess, or anastomotic complications. 3, 2
• Triggers for reassessment include: 3
  • Persistent organ dysfunction despite therapy
  • New or worsening abdominal pain
  • Inflammatory markers (WBC, CRP) not trending downward by day 3–4
  • Hemodynamic instability or new sepsis
• Inadequate source control—not antibiotic failure—is the most common cause of persistent infection and must be addressed surgically. 3, 7

Common Pitfalls to Avoid

• Do not delay source control while optimizing medical therapy; surgical intervention is the primary treatment, and antibiotics are adjunctive. 3, 2
• Do not continue broad-spectrum antibiotics beyond 5 days without clear justification, as this promotes multidrug-resistant organism acquisition without improving outcomes. 3, 2
• Do not use narrow-spectrum antibiotics in hospital-acquired peritonitis—resistance patterns demand broader coverage. 2
• Adjust antibiotic dosing based on renal function and pharmacokinetic parameters in critically ill patients to maintain therapeutic concentrations while minimizing toxicity. 3, 2
• Prior antibiotic exposure is the strongest modifiable risk factor for resistant organisms; always assess recent antimicrobial use and broaden coverage accordingly when risk factors are present. 3
• Inadequate or delayed source control independently predicts mortality even when antimicrobial therapy is appropriate. 1, 3, 7